![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SLC16A3 |
Gene summary for SLC16A3 |
![]() |
Gene information | Species | Human | Gene symbol | SLC16A3 | Gene ID | 9123 |
Gene name | solute carrier family 16 member 3 | |
Gene Alias | MCT 3 | |
Cytomap | 17q25.3 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | A0A024R8U1 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9123 | SLC16A3 | GSM4909296 | Human | Breast | IDC | 3.11e-02 | -9.83e-02 | 0.1524 |
9123 | SLC16A3 | GSM4909298 | Human | Breast | IDC | 3.11e-02 | -9.60e-02 | 0.1551 |
9123 | SLC16A3 | GSM4909312 | Human | Breast | IDC | 3.11e-02 | -9.36e-02 | 0.1552 |
9123 | SLC16A3 | GSM4909317 | Human | Breast | IDC | 1.47e-11 | 4.59e-01 | 0.1355 |
9123 | SLC16A3 | GSM4909319 | Human | Breast | IDC | 1.89e-02 | -6.87e-02 | 0.1563 |
9123 | SLC16A3 | GSM4909321 | Human | Breast | IDC | 2.80e-03 | 1.84e-01 | 0.1559 |
9123 | SLC16A3 | ctrl6 | Human | Breast | Precancer | 6.25e-03 | 3.54e-01 | -0.0061 |
9123 | SLC16A3 | brca3 | Human | Breast | Precancer | 1.71e-11 | 4.02e-01 | -0.0263 |
9123 | SLC16A3 | brca10 | Human | Breast | Precancer | 7.10e-13 | 5.08e-01 | -0.0029 |
9123 | SLC16A3 | NCCBC14 | Human | Breast | DCIS | 1.20e-02 | 2.81e-02 | 0.2021 |
9123 | SLC16A3 | NCCBC3 | Human | Breast | DCIS | 1.18e-04 | 2.15e-01 | 0.1198 |
9123 | SLC16A3 | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.40e-04 | 4.59e-01 | -0.1808 |
9123 | SLC16A3 | HTA11_1938_2000001011 | Human | Colorectum | AD | 2.02e-05 | 3.93e-01 | -0.0811 |
9123 | SLC16A3 | HTA11_411_2000001011 | Human | Colorectum | SER | 4.09e-02 | 1.04e+00 | -0.2602 |
9123 | SLC16A3 | HTA11_2112_2000001011 | Human | Colorectum | SER | 1.54e-05 | 8.27e-01 | -0.2196 |
9123 | SLC16A3 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.45e-04 | 1.72e-01 | -0.1464 |
9123 | SLC16A3 | HTA11_1391_2000001011 | Human | Colorectum | AD | 7.45e-04 | 2.17e-01 | -0.059 |
9123 | SLC16A3 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.42e-03 | 1.41e-01 | 0.294 |
9123 | SLC16A3 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.63e-04 | 1.90e-01 | 0.3859 |
9123 | SLC16A3 | LZE4T | Human | Esophagus | ESCC | 8.05e-04 | 2.50e-02 | 0.0811 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa052309 | Breast | Precancer | Central carbon metabolism in cancer | 13/684 | 70/8465 | 3.57e-03 | 2.17e-02 | 1.66e-02 | 13 |
hsa0523012 | Breast | Precancer | Central carbon metabolism in cancer | 13/684 | 70/8465 | 3.57e-03 | 2.17e-02 | 1.66e-02 | 13 |
hsa05230 | Colorectum | AD | Central carbon metabolism in cancer | 33/2092 | 70/8465 | 3.61e-05 | 3.19e-04 | 2.03e-04 | 33 |
hsa052301 | Colorectum | AD | Central carbon metabolism in cancer | 33/2092 | 70/8465 | 3.61e-05 | 3.19e-04 | 2.03e-04 | 33 |
hsa052302 | Colorectum | SER | Central carbon metabolism in cancer | 25/1580 | 70/8465 | 5.43e-04 | 4.51e-03 | 3.27e-03 | 25 |
hsa052303 | Colorectum | SER | Central carbon metabolism in cancer | 25/1580 | 70/8465 | 5.43e-04 | 4.51e-03 | 3.27e-03 | 25 |
hsa052304 | Colorectum | MSS | Central carbon metabolism in cancer | 25/1875 | 70/8465 | 6.50e-03 | 2.64e-02 | 1.62e-02 | 25 |
hsa052305 | Colorectum | MSS | Central carbon metabolism in cancer | 25/1875 | 70/8465 | 6.50e-03 | 2.64e-02 | 1.62e-02 | 25 |
hsa0523018 | Esophagus | ESCC | Central carbon metabolism in cancer | 50/4205 | 70/8465 | 1.70e-04 | 6.62e-04 | 3.39e-04 | 50 |
hsa0523019 | Esophagus | ESCC | Central carbon metabolism in cancer | 50/4205 | 70/8465 | 1.70e-04 | 6.62e-04 | 3.39e-04 | 50 |
hsa0523021 | Liver | HCC | Central carbon metabolism in cancer | 43/4020 | 70/8465 | 1.30e-02 | 3.19e-02 | 1.78e-02 | 43 |
hsa0523031 | Liver | HCC | Central carbon metabolism in cancer | 43/4020 | 70/8465 | 1.30e-02 | 3.19e-02 | 1.78e-02 | 43 |
hsa0523016 | Oral cavity | OSCC | Central carbon metabolism in cancer | 49/3704 | 70/8465 | 7.57e-06 | 3.59e-05 | 1.83e-05 | 49 |
hsa0523017 | Oral cavity | OSCC | Central carbon metabolism in cancer | 49/3704 | 70/8465 | 7.57e-06 | 3.59e-05 | 1.83e-05 | 49 |
hsa0523023 | Oral cavity | LP | Central carbon metabolism in cancer | 31/2418 | 70/8465 | 3.50e-03 | 1.46e-02 | 9.40e-03 | 31 |
hsa0523033 | Oral cavity | LP | Central carbon metabolism in cancer | 31/2418 | 70/8465 | 3.50e-03 | 1.46e-02 | 9.40e-03 | 31 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC16A3 | deletion | In_Frame_Del | novel | c.19_30delNNNNNNNNNNNN | p.Asp7_Pro10del | p.D7_P10del | O15427 | protein_coding | TCGA-AC-A8OQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
SLC16A3 | SNV | Missense_Mutation | c.1030N>G | p.Met344Val | p.M344V | O15427 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-Q1-A5R3-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PR | |
SLC16A3 | SNV | Missense_Mutation | novel | c.701N>T | p.Ala234Val | p.A234V | O15427 | protein_coding | deleterious(0) | probably_damaging(0.924) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC16A3 | SNV | Missense_Mutation | rs751794791 | c.878N>G | p.Tyr293Cys | p.Y293C | O15427 | protein_coding | deleterious(0) | possibly_damaging(0.84) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
SLC16A3 | SNV | Missense_Mutation | c.302N>A | p.Gly101Asp | p.G101D | O15427 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-G4-6586-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SLC16A3 | SNV | Missense_Mutation | rs754295601 | c.955N>A | p.Gly319Ser | p.G319S | O15427 | protein_coding | tolerated(0.53) | benign(0.072) | TCGA-A5-A2K3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
SLC16A3 | SNV | Missense_Mutation | novel | c.416N>T | p.Arg139Leu | p.R139L | O15427 | protein_coding | tolerated(0.26) | benign(0.053) | TCGA-AJ-A3EM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC16A3 | SNV | Missense_Mutation | novel | c.1099G>A | p.Val367Met | p.V367M | O15427 | protein_coding | deleterious(0.04) | probably_damaging(1) | TCGA-D1-A16Y-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SLC16A3 | SNV | Missense_Mutation | novel | c.22N>A | p.Glu8Lys | p.E8K | O15427 | protein_coding | tolerated(0.29) | benign(0.037) | TCGA-D1-A1O7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SLC16A3 | SNV | Missense_Mutation | novel | c.1178N>T | p.Ala393Val | p.A393V | O15427 | protein_coding | tolerated(0.4) | benign(0.01) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
9123 | SLC16A3 | DRUGGABLE GENOME, TRANSPORTER | STZ | STREPTOZOCIN | 12611763 |
Page: 1 |